


In Advanced Prostate Cancer... Bone Metastatic Migration Impacts Survival¹



90% OF MEN WITH ADVANCED PROSTATE CANCER DEVELOP BONE METASTASES²

Prostate cancer preferentially metastasizes to bone via “seed” and “soil”³



Impact your patients’ prognosis when bone metastases are fewer, early in mCRPC

- Patients with ≥ 5 metastases have significantly reduced overall survival and progression-free survival vs 1-4 metastases⁵


In Advanced Prostate Cancer... Bone Metastatic Migration Impacts Survival¹



SURVIVAL DECLINES WITH THE SPREAD OF METASTASES⁶

Median Survival (95% CI)

Lymph Nodes	Bone	Visceral	Bone plus Visceral
43 (35.1-50.9)	24 (22.9-25.1)	16 (12.9-19.1)	14 (12.0-15.9)



Significant differences exist in overall survival in mCRPC patients depending on location of metastasis⁶

- A marked reduction in survival is seen in patients with bone plus visceral metastases compared to bone-only metastatic disease⁶

When prostate cancer spreads to the bone, focus your clinical approach on bone metastases

CI, confidence interval; mCRPC, metastatic castration-resistant prostate cancer.

References: 1. Nørgaard M, Jensen AØ, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). *J Urol.* 2010;184(1):162-167. 2. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. *Hum Pathol.* 2000;31(5):578-583. 3. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. *Cell Res.* 2005;15(1):57-62. 4. Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. *Nature.* 2015;520(7547):353-357. 5. Tait C, Moore D, Hodgson C, et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. *BJU Int.* 2014;114: E70-E73. 6. Gandaglia G, Karakiewicz PI, Briganti A, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. *Eur Urol.* 2015;68(2):325-334.